

Investor Newsletter

Issue **11** 2020




Firehawk™ Stent, Firefighter™ PTCA Balloon Catheter and Two Other MicroPort® Products Approved for Launch in Ecuador

Recently, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") has received marketing approval from the Regulatory, Control and Surveillance National Agency of Ecuador (La Agencia Nacional de Regulación, Control y Vigilancia Sanitaria — ARCSA) for its proprietary products Firehawk™ Rapamycin Target Eluting Coronary Stent System (Firehawk™), Firebird2™ Coronary Rapamycin-Eluting CoCr Stent System (Firebird2™), Firefighter™ PTCA Balloon Catheter (Firefighter™) and FOXTROT™ NC PTCA Balloon Catheter (FOXTROT™ NC).

The approval of the four MicroPort® products in Ecuador, particularly the Firehawk™ stent, not only shows industry recognition of MicroPort® for its outstanding product portfolio in the field of coronary intervention, but also further expands the company's global presence. Now, the company's coronary interventional products have been introduced to more than 4,000 hospitals in more than 50 countries around the world, covering major markets in Asia Pacific, Europe and South America, and have won the trust and recognition of doctors and patients in clinical applications.

In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians around the world with higher-quality, innovative high-end medical devices and integrated solutions.



First Implantation of Endovastec™ Minos™ Stent Graft System Completed in Argentina

The first implantation of the Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ Stent Graft System”) developed by the Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”) was successfully completed in Argentina. This is the seventh market — and the first in South America — that Minos™ Stent Graft System has entered, following Greece, Poland, Spain, Germany, Italy and Switzerland.

The implantation of the Minos™ Stent Graft System was performed by a team led by Dr. Mauricio Bonet and Dr. Mariano Campenni from Sanatorio Junin Hospital in Buenos Aires. The low-profile design of the Minos™ System reduces the damage to the access vessel during the operation, while the proximal tip-capture mechanism and excellent compliance performance of the stent can ensure the accurate placement of the stent graft and the stable isolation of the aneurysm. The angiography showed that the aneurysm was effectively isolated, the stent graft well conformed to the patient’s anatomy and the blood flow in the branch stent was restored, indicating a successful operation.

The first clinical implantation of the Minos™ Stent Graft System in Argentina marks the entry of Endovastec™ into the South America market. In the future, Endovastec™ will continue to cooperate with overseas clinical experts to bring more high-quality, innovative and sophisticated medical devices to the global market for the benefit of more patients with aortic and peripheral vascular diseases.




Firehawk™ Debuted at **Semana SBHCI 2020**

Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) recently unveiled Firehawk™ Rapamycin Target Eluting Coronary Stent System (Firehawk™) at the Brazilian Society of Hemodynamics and Interventional Cardiology Annual Congress (Semana SBHCI 2020), held virtually from November 2–6th 2020. The event was attended by around 2,000 experts and professionals in the field of cardiovascular interventions from more than 30 countries and covered the latest developments in the industry and academia.

On the morning of November 6th, Prof. Chen Shaoliang, Prof. Zhang Junjie, Prof. Ye Fei and Dr. You Wei from the Department of Cardiology, Nanjing First Hospital, presented two interventional procedure cases live on complex coronary bifurcation lesions, which were skillfully performed. The Firehawk™ stent was selected in both procedures, being recognized by the experts at the conference for its excellent crossability during procedures and its superior vessel wall apposition.

Prof. Ricardo A. Costa, Chairman of the Congress, who is based in the host country of Brazil, spoke highly of the outstanding performance of the cardiology team of Nanjing First Hospital, and fully recognized the clinical performance of the Firehawk™ stent.



As one of the most important markets in South America, Brazil has an enormous market potential for medical devices and a high demand for cardiovascular interventional products. Under this backdrop, Microport® products such as the Firehawk™ Stent and the Firefighter™ Balloon Catheter have received trust and recognition from doctors and patients for their use in Brazil.



MicroPort® RIC MedTech™ Attended **CMEF 2020**

Suzhou MicroPort RIC MedTech Ltd. (RIC MedTech™), a subsidiary of MicroPort®, recently attended the 83rd China International Medical Equipment Fair (CMEF), held from October 19-22 at the National Exhibition and Convention Center in Shanghai, to showcase more than ten of its rehabilitation and patient care products. With the theme of “Innovative Technologies Lead the Future”, the event attracted more than 4,000 exhibitors and 100,000 professionals in the industry from around the world, both virtually and in-person.

At CMEF, RIC MedTech™ displayed the full range of its musculoskeletal rehabilitation, sports rehabilitation, cardiopulmonary rehabilitation, and rehabilitation care solutions. Among them, the cardiopulmonary exercise testing system and aerobic training system for cardiopulmonary rehabilitation, which combines the function of monitored aerobic exercises with respiratory assessment and dynamic 12-lead ECG assessment to realize integration of assessment, training, monitoring, and data management. It is also equipped with different hardware and assessment options that can meet the needs of patients with different diseases and treatment cycles. This enables cardiopulmonary rehabilitation to be supported by safe, effective, and scientific solutions. At the exhibition, many medical professionals and visitors tried this system and were inquiring about product details and eagerly exploring partnership opportunities.

Due to COVID-19, many professionals in the industry were unable to attend CMEF in person this year, so RIC MedTech™ organized a “Cloud Tour” of its booth and a two-day live broadcast during the exhibition on two themes, “sports rehabilitation solutions” and “musculoskeletal rehabilitation and rehabilitation care solutions”, to introduce its products and answer related questions.

MicroPort® Awarded **"Best Open Innovator 2020"** at the Fifth China Innovation Challenge and the Third Yangtze River Delta International Innovation Challenge Special Tournament

Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort") was recently awarded "Best Open Innovator 2020" for the Dr. X Competition on Doctor and Medical Device Innovation. As one of 43 dedicated events at the Fifth China Innovation Challenge (Special Tournament on the Integrated Development of the Yangtze River Delta) and the Third Yangtze River Delta International Innovation Challenge, the event was co-organized by MicroPort® and attended by the MicroPort® Senior Vice President for Technology Innovation and New Business Development, Dr. He Xiang.

With a focus on ensuring open innovation within large enterprises and taking the theme of "Medical-engineering collaboration for the accelerated commercialization of medical device innovations", MicroPort® organized the Dr. X Competition with the aim of breaking down the barriers between clinical and engineering professionals and promoting the appropriate exchange of scientific and technological resources between doctors and engineers, thereby advancing the commercialization of medical device innovations to prolong and reshape the lives of patients everywhere.


According to Dr. He Xiang, "winning the Best Open Innovator 2020 not only signifies the acknowledgement by the Shanghai Municipal Science and Technology Commission (SMSTC) and the NETC on the achievements of MicroPort® in exploring clinical needs and innovative solutions, but is also an indication of their support and encouragement for the partnership model of medical-engineering collaboration for innovation." At the ceremony, MicroPort® also discussed future cooperation with representatives of SMSTC and NETC to develop a new ecosystem for the commercialization of scientific and technological outcomes.



MicroPort® NeuroTech Named 2020 Shanghai High-tech “Little Giant” Enterprise

Shanghai MicroPort NeuroTech Co., Ltd. (“MicroPort® NeuroTech”) was recently named Shanghai High-tech “Little Giant” Enterprise by the Shanghai Municipal Science and Technology Commission.

The High-tech “Little Giant” Enterprise Program is an initiative introduced by the Shanghai Municipal Science and Technology Commission and Shanghai Municipal Commission of Economic and Informatization. The program aims to nurture technology-based enterprises with domestic and international competitive advantages, thereby further promoting independent innovation by small and medium-size high-tech enterprises and improving their core competitiveness. MicroPort® NeuroTech has been recognized for its innovation, scale and exemplary role based on assessments by the district and municipal authorities on multiple dimensions. This includes its innovation system and mechanisms, investment in scientific research, independent intellectual property rights, economic scale, growth potentials, as well as credit and financing ability.



The selection of MicroPort® NeuroTech as a High-tech “Little Giant” Enterprise signifies the recognition by the Shanghai Municipal Government on the company’s improved innovation system, independent innovation capability and comprehensive management strength. MicroPort® NeuroTech will continue to embrace scientific and technological innovation, strengthen its core competitiveness, expand domestic and international markets, and commit itself to becoming a “total solution provider for cerebral apoplexy” for the benefit of more patients in the future.

Investor Newsletter

Issue **11** 2020



For more information, please contact:

Martin Sun

Chief Financial Officer
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com

Leanne Li

Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com